Efficacy and Safety of Immunosuppressant Therapy for Noninfectious Uveitis: A Systematic Review and Meta-Analysis

Table 1

Baseline information of included literature.

Author	Year	Type of study	Intervention (treatment vs. control)	Patients (treatment/control)	Female (treatment/control)	Efficacy (yes/no) treatment vs. control
Nguyen et al.	2016	RCT, DB	Adalimumab vs. placebo	115/111	66/72	70/45 vs. 50/61
Jaffe et al.	2016	RCT, DB	Adalimumab vs. placebo	—	—	—
Ramanan et al.	2017	RCT, DB	Adalimumab vs. placebo	60/30	47/23	44/16 vs. 12/18
Quartier et al.	2017	RCT, DB	Adalimumab vs. placebo	16/15	15/13	9/7 vs. 3/12
Cecchin et al.	2018	Prospective study	Adalimumab vs. infliximab	95/59	16/15	57/38 vs. 12/47
Heissigerová et al.	2018	RCT, DB	Sarilumab vs. placebo	38/20	23/13	29/9 vs. 15/5
Rathinam et al.	2019	RCT, SB	Methotrexate vs. mycophenolate mofetil	107/109	75/60	64/43 vs. 56/53

RCT: randomized controlled trial; DB: double-blind; SB: single-blind; DMARDs: disease-modifying antirheumatic drugs.